Type‑level analysis of the Swine Feed Probiotic Yeast market distinguishes three product families: live yeast cultures, yeast cell‑wall extracts, and fermented yeast metabolites. Live yeast products, typically Saccharomyces cerevisiae strains, are administered as viable cells that colonise the gastrointestinal tract; they dominate the premium segment because of their dual role in competitive exclusion and enzymatic supplementation, contributing an estimated 45 % of volume sales. Yeast cell‑wall extracts—principally β‑glucan and mannan‑oligosaccharide fractions—are non‑viable, heat‑stable powders valued for immunomodulatory effects; they capture roughly 30 % of market value, driven by ease of integration into pelleted feeds and consistent functional performance. Fermented yeast metabolites encompass organic acids, peptides, and vitamins produced during controlled fermentation; this sub‑type accounts for about 25 % of revenue, as manufacturers leverage its targeted antimicrobial activity to replace in‑feed antibiotics. Each type aligns with distinct production logistics, cost structures, and efficacy profiles, shaping overall market dynamics and influencing strategic positioning of suppliers.